GSK agreed to acquire Nuvalent for approximately $10.6 billion. The purchase price is $124 per share. This represents a 40% premium to the last closing price. The transaction marks GSK’s third acquisition of 2026. It is the company's largest deal of the year and the second-biggest in the biopharma industry.
The deal adds two lung cancer drugs, zidesamtinib and neladalkib, to GSK’s portfolio. Both treatments are currently under FDA review. Regulatory decisions are expected by the end of 2026. GSK anticipates these drugs will generate new revenue starting in 2027.
This acquisition strengthens GSK’s precision oncology capabilities. The strategy aims to offset future revenue losses from upcoming patent expirations.